- Home
- IMMX vs PRLD Comparison
IMMX vs PRLD Comparison
Compare IMMX & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- PRLD
- Stock Information
- Founded
- IMMX 2014
- PRLD 2016
- Country
- IMMX United States
- PRLD United States
- Employees
- IMMX N/A
- PRLD N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- IMMX Health Care
- PRLD Health Care
- Exchange
- IMMX Nasdaq
- PRLD Nasdaq
- Market Cap
- IMMX 46.8M
- PRLD 53.4M
- IPO Year
- IMMX 2021
- PRLD 2020
- Fundamental
- Price
- IMMX $1.67
- PRLD $0.95
- Analyst Decision
- IMMX Strong Buy
- PRLD Buy
- Analyst Count
- IMMX 1
- PRLD 3
- Target Price
- IMMX $7.00
- PRLD $5.33
- AVG Volume (30 Days)
- IMMX 89.1K
- PRLD 412.6K
- Earning Date
- IMMX 11-12-2024
- PRLD 11-06-2024
- Dividend Yield
- IMMX N/A
- PRLD N/A
- EPS Growth
- IMMX N/A
- PRLD N/A
- EPS
- IMMX N/A
- PRLD N/A
- Revenue
- IMMX N/A
- PRLD $3,000,000.00
- Revenue This Year
- IMMX N/A
- PRLD N/A
- Revenue Next Year
- IMMX $200.00
- PRLD N/A
- P/E Ratio
- IMMX N/A
- PRLD N/A
- Revenue Growth
- IMMX N/A
- PRLD N/A
- 52 Week Low
- IMMX $1.26
- PRLD $0.93
- 52 Week High
- IMMX $7.75
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- IMMX 50.69
- PRLD 21.77
- Support Level
- IMMX $1.65
- PRLD $0.93
- Resistance Level
- IMMX $1.93
- PRLD $1.36
- Average True Range (ATR)
- IMMX 0.16
- PRLD 0.09
- MACD
- IMMX 0.01
- PRLD 0.03
- Stochastic Oscillator
- IMMX 42.55
- PRLD 8.44
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.